v3.25.1
Summary of Significant Accounting Policies - Schedule of Percentage of Revenue and Accounts Receivables from Customers (Details) - Customer Concentration Risk
3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Revenue | Moderna Inc      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk percentage 27.00% 24.00%  
Revenue | VA MVP      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk percentage 20.00%    
Revenue | Natera Inc.      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk percentage 12.00% 41.00%  
Accounts Receivable | Moderna Inc      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk percentage 14.00%    
Accounts Receivable | VA MVP      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk percentage 11.00%    
Accounts Receivable | Pfizer Inc.      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk percentage 26.00%   25.00%
Accounts Receivable | Merck & Co., Inc.      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk percentage     31.00%
Accounts Receivable | Natera Inc.      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk percentage     13.00%
Accounts Receivable | AstraZeneca UK Limited      
Summary Of Significant Accounting Policies [Line Items]      
Concentration risk percentage 18.00%